you will notice that the .55log results are for m184v + >3 TAMS... ie these are ppl that have developed significant resistant to current drugs. admittedly Racivir does better in these ppl with a .7log drop. however the bulk of the market remains in the m184v +<3 space... ie those ppl with drug resistance... but not huge drug resistance. it is in this space that ACT excels with 1.1log drop the best result in its class (NRTI)
